bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com

StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a note issued to investors on Friday. The firm set a “sell” rating on the biotechnology company’s stock.

BLUE has been the topic of several other reports. JPMorgan Chase & Co. lowered shares of bluebird bio from an “overweight” rating to a “neutral” rating in a research report on Thursday, August 15th. Barclays cut their target price on shares of bluebird bio from $8.00 to $4.00 and set an “overweight” rating for the company in a research note on Thursday, August 15th. Cantor Fitzgerald reissued a “neutral” rating on shares of bluebird bio in a report on Monday, September 16th. Robert W. Baird lowered their target price on bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday, August 15th. Finally, Bank of America lowered their price target on shares of bluebird bio from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Thursday, August 15th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, bluebird bio presently has a consensus rating of “Hold” and a consensus price target of $4.63.

bluebird bio Stock Performance

Shares of BLUE opened at $0.48 on Friday. bluebird bio has a 12-month low of $0.45 and a 12-month high of $5.53. The firm’s 50 day moving average is $0.54 and its 200-day moving average is $0.84. The stock has a market capitalization of $52.50 million, a P/E ratio of -0.65 and a beta of 0.75. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.68 and a quick ratio of 0.57.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. bluebird bio had a negative return on equity of 207.25% and a negative net margin of 567.29%. The company had revenue of $18.57 million during the quarter. Equities research analysts anticipate that bluebird bio will post -1.42 EPS for the current fiscal year.

Institutional Trading of bluebird bio

A number of large investors have recently bought and sold shares of BLUE. Sequoia Financial Advisors LLC raised its stake in bluebird bio by 48.0% in the first quarter. Sequoia Financial Advisors LLC now owns 40,085 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 13,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of bluebird bio by 38.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 325,111 shares of the biotechnology company’s stock worth $416,000 after buying an additional 90,139 shares during the period. SG Americas Securities LLC grew its holdings in bluebird bio by 458.8% in the first quarter. SG Americas Securities LLC now owns 80,032 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 65,710 shares during the period. Vanguard Group Inc. increased its position in bluebird bio by 19.6% during the 1st quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock valued at $13,438,000 after buying an additional 1,723,081 shares in the last quarter. Finally, American International Group Inc. increased its holdings in shares of bluebird bio by 77.4% during the first quarter. American International Group Inc. now owns 94,371 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 41,177 shares in the last quarter. 87.43% of the stock is owned by hedge funds and other institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.